Skip to main content

Published

Photobiomodulation for cognitive dysfunction (Brain Fog) in post-COVID-19 condition: a randomized double-blind sham-controlled pilot trial.
Lim L. eClinicalMedicine 2026;:https://doi.org/10.1016/j.eclinm.2025.103730.
[Post-COVID-19 condition (PCC) affects millions globally, with cognitive dysfunction (“brain fog”) impairing daily functioning in up to 88% of patients. Home-based photobiomodulation is safe and feasible, showing potential cognitive benefits for PCC brain fog, particularly in younger adults. Larger trials are needed to confirm efficacy and optimize parameters.]
Freely available online

Age Groups
Adults
Young People
Conditions and Lifestyle Factors
Cognitive Symptoms
Coronavirus Infections
Professional Interests
Design of Care Pathways
Settings
Community Clinics
General Practice
Staff Groups